STOCK TITAN

Staar Surgical Co - $STAA STOCK NEWS

Welcome to our dedicated page for Staar Surgical Co news (Ticker: $STAA), a resource for investors and traders seeking the latest updates and insights on Staar Surgical Co stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Staar Surgical Co's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Staar Surgical Co's position in the market.

Rhea-AI Summary
STAAR Surgical Company announced its participation in several upcoming investor conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.47%
Tags
conferences
-
Rhea-AI Summary
STAAR Surgical Company (NASDAQ: STAA) reported financial results for Q2 2023. Net sales were $92.3 million, up 14% YoY. Record ICL sales reached $93.1 million, up 19% YoY. Gross margin was 76.6%, down from 78.8% in the prior year quarter. Net income was $0.12 per share, compared to $0.26 per share in the prior year quarter. Cash, cash equivalents, and investments totaled $209.5 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.6%
Tags
-
Rhea-AI Summary
STAAR Surgical Company (NASDAQ: STAA) to Release Q2 2023 Financial Results on August 2, 2023. Conference Call and Webcast to Discuss Financial Results and Operational Progress. Access Details Included.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
conferences earnings
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.78%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.78%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.24%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.43%
Tags
none
Staar Surgical Co

Nasdaq:STAA

STAA Rankings

STAA Stock Data

2.26B
37.60M
0.78%
107.7%
10.79%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
MONROVIA

About STAA

staar surgical company (nasdaq: staa), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye has been dedicated solely to ophthalmic surgery for over 30 years. the company offers the evo visian implantable collamer® lenses (icls) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and hyperopic icl, which treats far-sightedness. these lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. all of these lenses are foldable, which permits the surgeon to insert them through a small incision. staar's lens used in refractive surgery is called an implantable collamer lens or "icl"​. nearly 600,000 visian icls have been implanted to date. it also provides minimally invasive intraocular lenses (iols), including foldable iols for use in minimally invasive cataract surgical procedures; aspheric iols that produce a clearer image than trad